骨髓增生异常-话题@MedSci

#骨髓增生异常#

77篇内容 | 1108人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2169468, encodeId=bb6c21694687c, content=<a href='/topic/show?id=5d3d53e27bd' target=_blank style='color:#2F92EE;'>#慢性髓系白血病#</a> <a href='/topic/show?id=c15f10196028' target=_blank style='color:#2F92EE;'>#骨髓增殖性肿瘤#</a> <a href='/topic/show?id=b3ca22204c1' target=_blank style='color:#2F92EE;'>#中性粒细胞增多#</a> <a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=【Blood Adv】347例不典型慢性髓系白血病的特征、初始治疗和生存：荷兰基于人群的研究, objectType=article, longId=801243, objectId=d11280124371, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-PX4RLTJ.jpg, objectUrl=/article/show_article.do?id=d11280124371, replyNumber=0, likeNumber=23, createdTime=2023-11-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d11280124371, moduleTitle=【Blood Adv】347例不典型慢性髓系白血病的特征、初始治疗和生存：荷兰基于人群的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d11280124371)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2004241, encodeId=bb2d2004241df, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=haematol： DDX41突变在意义不明的特发性血细胞减少症、骨髓增生异常综合征或急性髓细胞白血病患者中的独特种族特征 , objectType=article, longId=299300, objectId=6c4d299300d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c4d299300d6, replyNumber=0, likeNumber=41, createdTime=2022-05-10, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c4d299300d6, moduleTitle=haematol： DDX41突变在意义不明的特发性血细胞减少症、骨髓增生异常综合征或急性髓细胞白血病患者中的独特种族特征 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c4d299300d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004240, encodeId=3f262004240e4, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=Ann Hematol：急性移植物抗宿主病增加骨髓增生异常综合征患者移植相关血栓性微血管病预测模型的风险和准确性, objectType=article, longId=302301, objectId=32c8302301b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32c8302301b4, replyNumber=0, likeNumber=42, createdTime=2023-01-01, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32c8302301b4, moduleTitle=Ann Hematol：急性移植物抗宿主病增加骨髓增生异常综合征患者移植相关血栓性微血管病预测模型的风险和准确性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32c8302301b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004238, encodeId=173c2004238c0, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=小剂量阿克拉霉素治疗骨髓增生异常综合征2例, objectType=article, longId=220752, objectId=737a220e52dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=737a220e52dc, replyNumber=0, likeNumber=42, createdTime=2022-10-16, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=737a220e52dc, moduleTitle=小剂量阿克拉霉素治疗骨髓增生异常综合征2例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=737a220e52dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004239, encodeId=90552004239ab, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=Leukemia ：罗特西普用于骨髓增生异常综合征/骨髓增生性肿瘤伴环状铁粒幼细胞和血小板增多症, objectType=article, longId=299893, objectId=d33a2998931b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d33a2998931b, replyNumber=0, likeNumber=46, createdTime=2022-03-24, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d33a2998931b, moduleTitle=Leukemia ：罗特西普用于骨髓增生异常综合征/骨髓增生性肿瘤伴环状铁粒幼细胞和血小板增多症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d33a2998931b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004237, encodeId=6e0d200423e56, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=Leukemia：艾曲波帕eltrombopag在骨髓增生异常综合征的PDX模型中的临床前评估, objectType=article, longId=213632, objectId=794621363207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=794621363207, replyNumber=0, likeNumber=41, createdTime=2022-01-03, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=794621363207, moduleTitle=Leukemia：艾曲波帕eltrombopag在骨髓增生异常综合征的PDX模型中的临床前评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=794621363207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004236, encodeId=24462004236f8, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=JCO：口服阿扎胞苷对低风险骨髓增生异常综合征患者的影响, objectType=article, longId=209205, objectId=36c4209205ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36c4209205ac, replyNumber=0, likeNumber=49, createdTime=2021-11-22, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36c4209205ac, moduleTitle=JCO：口服阿扎胞苷对低风险骨髓增生异常综合征患者的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36c4209205ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004235, encodeId=6d06200423584, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=J Clin Oncol：骨髓增生异常综合征 | 基于临床和遗传特征的个体化预后预测, objectType=article, longId=206824, objectId=f620206824b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f620206824b5, replyNumber=0, likeNumber=46, createdTime=2021-03-29, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f620206824b5, moduleTitle=J Clin Oncol：骨髓增生异常综合征 | 基于临床和遗传特征的个体化预后预测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f620206824b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004234, encodeId=c6b020042348d, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=J Clin Oncol：来那度胺可恢复骨髓增生异常综合征对EPOα的敏感性，改善患者预后, objectType=article, longId=206296, objectId=888e206296e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=888e206296e7, replyNumber=0, likeNumber=37, createdTime=2021-05-29, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=888e206296e7, moduleTitle=J Clin Oncol：来那度胺可恢复骨髓增生异常综合征对EPOα的敏感性，改善患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=888e206296e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004233, encodeId=24032004233d0, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点, objectType=article, longId=205306, objectId=719320530679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=719320530679, replyNumber=0, likeNumber=45, createdTime=2021-01-22, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=719320530679, moduleTitle=TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=719320530679)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004232, encodeId=3b33200423299, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=Aprea的Eprenetapopt尚未达到治疗TP53突变性骨髓增生异常综合症的主要终点, objectType=article, longId=204980, objectId=817f204980c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=817f204980c0, replyNumber=0, likeNumber=50, createdTime=2021-03-03, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=817f204980c0, moduleTitle=Aprea的Eprenetapopt尚未达到治疗TP53突变性骨髓增生异常综合症的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=817f204980c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004230, encodeId=978d20042300f, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=FDA批准地西他滨/cedazuridine联合治疗骨髓增生异常综合征, objectType=article, longId=197791, objectId=327a19e79151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=327a19e79151, replyNumber=0, likeNumber=36, createdTime=2020-09-23, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=327a19e79151, moduleTitle=FDA批准地西他滨/cedazuridine联合治疗骨髓增生异常综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=327a19e79151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004231, encodeId=353c2004231c4, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验, objectType=article, longId=203861, objectId=324020386153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=324020386153, replyNumber=0, likeNumber=32, createdTime=2020-12-15, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=324020386153, moduleTitle=中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=324020386153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004226, encodeId=196e2004226f0, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=JSH实践指南：血液恶性肿瘤—Ⅰ.白血病-6:骨髓增生异常综合征, objectType=article, longId=188777, objectId=28ae188e771f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28ae188e771f, replyNumber=0, likeNumber=23, createdTime=2020-05-28, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28ae188e771f, moduleTitle=JSH实践指南：血液恶性肿瘤—Ⅰ.白血病-6:骨髓增生异常综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28ae188e771f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004228, encodeId=69512004228d6, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=FDA批准Reblozyl治疗骨髓增生异常综合症相关的贫血, objectType=article, longId=191464, objectId=43e019146416, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43e019146416, replyNumber=0, likeNumber=35, createdTime=2020-12-09, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43e019146416, moduleTitle=FDA批准Reblozyl治疗骨髓增生异常综合症相关的贫血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43e019146416)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004227, encodeId=3fb9200422e08, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=Lancet haematol：Enasidenib治疗IDH2突变型骨髓增生异常综合征, objectType=article, longId=189592, objectId=c3fe18959242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3fe18959242, replyNumber=0, likeNumber=41, createdTime=2020-04-16, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3fe18959242, moduleTitle=Lancet haematol：Enasidenib治疗IDH2突变型骨髓增生异常综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3fe18959242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004229, encodeId=2ec820042296d, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=ARCH PATHOL LAB MED：来自儿童肿瘤组AAML0431的报告唐氏综合征、骨髓增生异常综合征和急性髓系白血病的病理特征, objectType=article, longId=194494, objectId=835e19449456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=835e19449456, replyNumber=0, likeNumber=39, createdTime=2020-11-14, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=835e19449456, moduleTitle=ARCH PATHOL LAB MED：来自儿童肿瘤组AAML0431的报告唐氏综合征、骨髓增生异常综合征和急性髓系白血病的病理特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=835e19449456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004219, encodeId=eecc200421947, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=NCCN临床实践指南：骨髓增生异常综合征（2020.V1）, objectType=article, longId=178712, objectId=630e1e8712c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=630e1e8712c4, replyNumber=0, likeNumber=35, createdTime=2020-05-01, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=630e1e8712c4, moduleTitle=NCCN临床实践指南：骨髓增生异常综合征（2020.V1）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=630e1e8712c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004224, encodeId=c2122004224a3, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=聚焦阿扎胞苷联合治疗骨髓增生异常综合征的重磅进展, objectType=article, longId=184424, objectId=be5518442420, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be5518442420, replyNumber=0, likeNumber=42, createdTime=2019-12-21, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be5518442420, moduleTitle=聚焦阿扎胞苷联合治疗骨髓增生异常综合征的重磅进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be5518442420)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004220, encodeId=a91f20042204c, content=<a href='/topic/show?id=4bac10196249' target=_blank style='color:#2F92EE;'>#骨髓增生异常#</a>, objectTitle=骨髓增生异常综合征的治疗：ASTX727已获美国FDA的孤儿药物指定, objectType=article, longId=178844, objectId=61061e884412, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61061e884412, replyNumber=0, likeNumber=31, createdTime=2020-05-01, rootId=0, userName=huangshifeng, userId=b30d401, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61061e884412, moduleTitle=骨髓增生异常综合征的治疗：ASTX727已获美国FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61061e884412)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

骨髓增生异常

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#慢性髓系白血病# #骨髓增殖性肿瘤# #中性粒细胞增多# #骨髓增生异常#

【Blood Adv】347例不典型慢性髓系白血病的特征、初始治疗和生存：荷兰基于人群的研究

2023-11-19发表于上海

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

haematol： DDX41突变在意义不明的特发性血细胞减少症、骨髓增生异常综合征或急性髓细胞白血病患者中的独特种族特征

2022-05-10

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

Ann Hematol：急性移植物抗宿主病增加骨髓增生异常综合征患者移植相关血栓性微血管病预测模型的风险和准确性

2023-01-01

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

小剂量阿克拉霉素治疗骨髓增生异常综合征2例

2022-10-16

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

Leukemia ：罗特西普用于骨髓增生异常综合征/骨髓增生性肿瘤伴环状铁粒幼细胞和血小板增多症

2022-03-24

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

Leukemia：艾曲波帕eltrombopag在骨髓增生异常综合征的PDX模型中的临床前评估

2022-01-03

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

JCO：口服阿扎胞苷对低风险骨髓增生异常综合征患者的影响

2021-11-22

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

J Clin Oncol：骨髓增生异常综合征 | 基于临床和遗传特征的个体化预后预测

2021-03-29

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

J Clin Oncol：来那度胺可恢复骨髓增生异常综合征对EPOα的敏感性，改善患者预后

2021-05-29

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点

2021-01-22

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

Aprea的Eprenetapopt尚未达到治疗TP53突变性骨髓增生异常综合症的主要终点

2021-03-03

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

FDA批准地西他滨/cedazuridine联合治疗骨髓增生异常综合征

2020-09-23

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验

2020-12-15

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

JSH实践指南：血液恶性肿瘤—Ⅰ.白血病-6:骨髓增生异常综合征

2020-05-28

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

FDA批准Reblozyl治疗骨髓增生异常综合症相关的贫血

2020-12-09

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

Lancet haematol：Enasidenib治疗IDH2突变型骨髓增生异常综合征

2020-04-16

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

ARCH PATHOL LAB MED：来自儿童肿瘤组AAML0431的报告唐氏综合征、骨髓增生异常综合征和急性髓系白血病的病理特征

2020-11-14

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

NCCN临床实践指南：骨髓增生异常综合征（2020.V1）

2020-05-01

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

聚焦阿扎胞苷联合治疗骨髓增生异常综合征的重磅进展

2019-12-21

huangshifeng (审核中...)

前往app查看评论内容

#骨髓增生异常#

骨髓增生异常综合征的治疗：ASTX727已获美国FDA的孤儿药物指定

2020-05-01

科室
- - 订阅+
  - 更多科室
工具
服务